Cargando…
Endogenous Galectin-1 in T Lymphocytes Regulates Anti-prostate Cancer Immunity
The identification of effective new therapies for prostate cancer (PCa) requires a better understanding of the multiple molecular interactions between tumor cells and their associated microenvironment. In this context, galectin-1 (Gal-1) is a key molecule in the determination of the prostatic carcin...
Autores principales: | Corapi, Enrique, Carrizo, Gustavo, Compagno, Daniel, Laderach, Diego |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169479/ https://www.ncbi.nlm.nih.gov/pubmed/30319642 http://dx.doi.org/10.3389/fimmu.2018.02190 |
Ejemplares similares
-
Inhibition of galectins in cancer: Biological challenges for their clinical application
por: Laderach, Diego José, et al.
Publicado: (2023) -
Galectins as Checkpoints of the Immune System in Cancers, Their Clinical Relevance, and Implication in Clinical Trials
por: Compagno, Daniel, et al.
Publicado: (2020) -
Combining inhibition of galectin-3 with and before a therapeutic vaccination is critical for the prostate-tumor-free outcome
por: Tiraboschi, Carolina, et al.
Publicado: (2020) -
Unraveling How Tumor-Derived Galectins Contribute to Anti-Cancer Immunity Failure
por: Laderach, Diego José, et al.
Publicado: (2021) -
Galectins as New Prognostic Markers and Potential Therapeutic Targets for Advanced Prostate Cancers
por: Laderach, Diego J., et al.
Publicado: (2013)